CRDL
Price:
$1.83
Market Cap:
$173.53M
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation i...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
2019-01-15
Stock Exchange
NASDAQ
Ticker
CRDL
According to Cardiol Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -5.72. This represents a change of 30.02% compared to the average of -4.40 of the last 4 quarters.
The mean historical PE Ratio of Cardiol Therapeutics Inc. over the last ten years is -12.73. The current -5.72 PE Ratio has changed 4.39% with respect to the historical average. Over the past ten years (40 quarters), CRDL's PE Ratio was at its highest in in the December 2022 quarter at -1.47. The PE Ratio was at its lowest in in the March 2018 quarter at -49.66.
Average
-12.73
Median
-4.02
Minimum
-64.36
Maximum
-1.40
Discovering the peaks and valleys of Cardiol Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 83.31%
Maximum Annual PE Ratio = -1.40
Minimum Annual Increase = -92.33%
Minimum Annual PE Ratio = -64.36
Year | PE Ratio | Change |
---|---|---|
2023 | -2.56 | 83.31% |
2022 | -1.40 | -56.31% |
2021 | -3.19 | -20.58% |
2020 | -4.02 | -53.54% |
2019 | -8.66 | 75.32% |
2018 | -4.94 | -92.33% |
The current PE Ratio of Cardiol Therapeutics Inc. (CRDL) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.38
5-year avg
-3.97
10-year avg
-12.73
Cardiol Therapeutics Inc.’s PE Ratio is less than Flora Growth Corp. (-0.94), less than ABVC BioPharma, Inc. (-0.66), less than Indaptus Therapeutics, Inc. (-0.78), less than HCW Biologics Inc. (-0.69), less than PainReform Ltd. (-0.05),
Company | PE Ratio | Market cap |
---|---|---|
-0.94 | $13.31M | |
-0.66 | $8.19M | |
-0.78 | $14.58M | |
-0.69 | $26.62M | |
-0.05 | $1.81M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cardiol Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cardiol Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Cardiol Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for Cardiol Therapeutics Inc. (CRDL)?
What is the highest PE Ratio for Cardiol Therapeutics Inc. (CRDL)?
What is the 3-year average PE Ratio for Cardiol Therapeutics Inc. (CRDL)?
What is the 5-year average PE Ratio for Cardiol Therapeutics Inc. (CRDL)?
How does the current PE Ratio for Cardiol Therapeutics Inc. (CRDL) compare to its historical average?